OPEN MONOCLONAL TECHNOLOGY INC / LIGAND PHARMACEUTICALS INC / ESSEX WOODLANDS HEALTH VENTURES / Acquisition / Private

Synopsis

Acquisition by Ligand Pharmaceuticals of Open Monoclonal Technology, a biotechnology company engaged in genetic engineering of animals for the generation of human therapeutic antibodies.

Principals

target

Open Monoclonal Technology

bidder

Ligand Pharmaceuticals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (2)

matthew t. bush

Partner at Latham & Watkins

Lawyer

bidder

Deals

£ 13.19 B

Total Value

scott wolfe

Latham & Watkins

Lawyer

bidder

Deals

£ 178 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy